Return to Trial Database

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

Status

Currently Enrolling

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-AML20-472 being conducted in.

AdventHealth Orlando

Rhode Island Hospital

University of North Carolina Lineberger Comprehensive Cancer Center